Developer docs
API playgroundTry for free, no card

Search company profiles

I-Mak

Full company profile

uuid0005wpr

Namestring
I-Mak
Legal namestring
Initiative for Medicines, Access, and Knowledge
Websiteurl
i-mak.org
Company typeenum
Private
Founded yearint
2004
Descriptiontext

I-MAK (Initiative for Medicines, Access & Knowledge) is a 501(c)(3) nonprofit advocacy organization founded in 2004-2006 by Tahir Amin and Priti Krishtel, headquartered in Lewes, Delaware. The organization works on drug patent reform and access to medicines, producing policy research and litigation support aimed at reducing what it characterizes as anticompetitive pharmaceutical patent practices. Its work spans 49 countries and explicitly excludes pharmaceutical industry funding to preserve independence.

I-MAK's core analytical product is the Drug Patent Book, a curated patent database that underpins its published research outputs. These reports include "Overpatented, Overpriced" (with a 2025 edition focused on Medicare-negotiated drugs), "The Burden of Patent Thickets" (estimating ~$158 billion in cost burden), "The Costs of Pharma Cheating" (produced with the American Economic Liberties Project, estimating ~$40 billion annually), and "The Monopoly Extension Menu" on patent term extension strategies. The organization operates with a small team of 1-10 employees and is funded by a diversified base of major philanthropic foundations including the Ford Foundation, Open Society Foundations, Rockefeller Brothers Fund, Kaiser Permanente, and Arnold Ventures.

The business model is donation- and grant-based rather than commercial. I-MAK does not sell its reports or database access as revenue products; rather, it distributes research to influence regulators (notably the FTC and the Centers for Medicare & Medicaid Services), inform litigation, and shape media and policy discourse on drug pricing. Strategic significance derives from its role as a credible, independent counterweight to pharmaceutical industry patent strategy, with measurable downstream influence on U.S. drug-price negotiation policy.

Short descriptiontext

I-MAK is a 501(c)(3) nonprofit advocacy organization that conducts drug patent research and policy work to challenge anticompetitive pharmaceutical patenting, serving regulators, policymakers, litigators, journalists, and patient advocates across 49 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug patent research, pharmaceutical patent analytics, patent reform advocacy, drug pricing transparency, medicines access policy
Industry2 codes
PRIMARYBPAHAMAI
IP Search, Watch & Competitive Intelligence
SECONDARYMPAJACAK
IP & Patent Information Publishing (Patent/Litigation Analytics, Prior Art)
Media, Entertainment & Sports/Publishing (Books, News, Magazines)/Professional & Legal Publishing (Standards, Compliance, Reference)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Book Publishers51313
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Patent Research and Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Charitable Contributions and Grants
TypeOthers
Description

I-MAK is a 501(c)(3) nonprofit organization that relies on charitable contributions from foundations and individuals. The organization explicitly states they do not accept funding from branded or generic pharmaceutical companies to maintain independence and exclusively represent the interests of patients and consumers.

i-mak.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Drug Patent Book
Description

A publicly accessible, user-friendly database providing comprehensive patent data on top-selling prescription drugs in the U.S.

i-mak.org
+1 more record
Core offering1 text field

I-MAK conducts rigorous research on pharmaceutical patenting practices and operates the Drug Patent Book, a publicly accessible database tracking patent applications, granted patents, pricing, and spending data on top-selling prescription drugs in the U.S. The organization publishes annual research reports (Overpatented, Overpriced series), policy blueprints, and educational resources, and engages in advocacy and Congressional testimony to drive patent system reform aimed at lowering drug prices and expanding access to affordable medicines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Research cited in major media including NYT, TIME, Reuters, NBC, and featured in Congressional hearings
+3 more records
Product overview1 text field

I-MAK (Initiative for Medicines, Access, and Knowledge) is a nonprofit research and advocacy organization focused on patent reform and drug pricing transparency. The organization operates primarily through research and data products rather than a unified software platform. Its core offerings include The Drug Patent Book, a comprehensive publicly accessible database of drug patent information; annual Overpatented, Overpriced reports analyzing pharmaceutical patent abuse; The Burden of Patent Thickets study quantifying the $158 billion cost of extended patent protection; and the Addressing Patent Thickets Blueprint presenting policy solutions. These products work together to provide transparency on pharmaceutical patenting practices, educate stakeholders, and inform policy reform efforts aimed at lowering drug prices through patent system improvements.

Product and service9 records
1The Drug Patent Book
CategoryPatent Database
Description

A publicly accessible, user-friendly database providing comprehensive patent data on top-selling prescription drugs in the U.S., including patent applications, granted patents, filing dates, expiration dates, pricing, and spending information. Used by researchers, policymakers, journalists, and patient advocates.

2Overpatented, Overpriced Reports
CategoryResearch Report
Description

Annual analyses documenting how pharmaceutical manufacturers use patent strategies to extend monopoly pricing on drugs beyond original patent terms, with case studies on specific medications.

3The Burden of Patent Thickets Study
CategoryResearch Study
Description

A study exposing the $158 billion in revenue extracted by drugmakers on four biologic drugs (Humira, Avastin, Rituxan, and Lantus) through extended patent protection limiting biosimilar competition.

4Addressing Patent Thickets Blueprint
CategoryPolicy Blueprint
Description

A policy document presenting policymakers with approaches to address patent thickets, improve competition, and lower prescription drug prices through patent system reforms.

5Overpatented 2025: Eliquis and Semaglutide Analysis
CategoryResearch Report
Description

A 2025 data brief analyzing patenting and pricing practices for Medicare-negotiated drugs Eliquis, Ozempic, Rybelsus, and Wegovy, examining patent term extensions and follow-on patenting strategies.

6The Costs of Pharma Cheating Report
CategoryResearch Report
Description

A co-authored report with American Economic Liberties Project exposing how pharmaceutical companies combine abusive patenting strategies with anti-competitive tactics, estimating $40 billion annual cost to the American public.

7Biologics, Biosimilars and Patents: A Beginner's Guide
CategoryEducational Resource
Description

A beginner's guide explaining how biologics and biosimilars work and their relationship to the patent system.

8America's Top Selling Drugs Data Resource
CategoryData Resource
Description

A collection of statistics including market dynamics, pricing, spending data, and patent information for the top 10 best-selling drugs in America.

9Drug Pricing Survey Data
CategoryData Resource
Description

Survey data on drug pricing concerns, providing public insights into pharmaceutical pricing issues.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

MSF (Doctors Without Borders) is listed as an I-MAK supporter, aligning on access to medicines issues globally.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

I-MAK partnered with the American Economic Liberties Project on 'The Costs of Pharma Cheating' report, exposing how pharmaceutical industry abusive patenting tactics violate antitrust laws and cost Americans $40 billion annually.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

I-MAK provided data and analysis for Protect Our Care's report highlighting the impact Medicare negotiations will have on lowering drug prices and curbing patent abuse.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

I-MAK partnered with Public Citizen on advocacy letters to Senator Schumer calling for insulin reforms and drug pricing legislation.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

I-MAK joined with AARP and Patients for Affordable Drugs Now in joint letters urging Senate action to lower drug prices.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S. consumer advocacy nonprofit running a long-running access-to-medicines program that campaigns on drug pricing, opposes pharma patent abuse, and has partnered with I-MAK on Congressional advocacy. Direct peer in mission and tactics.

TypeDirect peer
Description

Nonprofit focused on IP policy and access-to-medicines issues, conducts original research on drug patenting and participates in WIPO/WTO deliberations. Directly comparable to I-MAK in patent-research and policy-advocacy niche.

TypeDirect peer
Description

The access-to-medicines arm of Doctors Without Borders; campaigns against pharma patent abuse, supports pool patents, and is listed as a mutual supporter of I-MAK. Operates in the same advocacy space with similar quantitative-impact framing.

4Patients For Affordable Drugs Now
TypeDirect peer
Description

U.S. patient-led advocacy organization pushing for drug-price reform and patent transparency; has co-signed advocacy letters with I-MAK. Directly comparable mission and Congressional-engagement model.

5Drug Pricing Lab at Memorial Sloan Kettering
TypeEmerging player
Description

Peter Bach's drug-pricing research initiative producing data-driven analyses on U.S. drug costs and policy. Comparable in producing evidence-based research on drug-pricing economics, though not patent-system-focused.

TypeDirect peer
Description

Anti-monopoly advocacy organization that co-authored 'The Costs of Pharma Cheating' with I-MAK. Operates in adjacent antitrust/competition space but with direct collaboration on I-MAK's patent-reform reports.

TypeEmerging player
Description

International policy NGO focused on development issues including access-to-medicines and IP reform. Comparable in publishing analyses on drug patenting for global policy audiences, primarily outside the U.S.

TypeEmerging player
Description

U.S.-based AIDS access advocacy organization with similar mission around pharmaceutical pricing transparency, particularly in HIV. Comparable in advocacy tactics though narrower therapeutic focus.

TypeBroad incumbent
Description

Commercial patent-analytics subscription service providing patent and exclusivity data on pharmaceuticals. Overlaps with I-MAK's Drug Patent Book but operates commercially with broader drug coverage; comparable product category.

10CIVIC (Center for Information and Innovation on the Pharmaceutical Industry) at USC Schaeffer
TypeEmerging player
Description

Academic research center producing independent analysis of pharmaceutical industry economics and policy. Comparable in producing evidence on drug pricing and IP issues though academic rather than advocacy orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

I-Mak

Pharmaceutical Patent Research and Advocacyi-mak.org

I-MAK is a 501(c)(3) nonprofit advocacy organization that conducts drug patent research and policy work to challenge anticompetitive pharmaceutical patenting, serving regulators, policymakers, litigators, journalists, and patient advocates across 49 countries.

What I-Mak does

I-MAK (Initiative for Medicines, Access & Knowledge) is a 501(c)(3) nonprofit advocacy organization founded in 2004-2006 by Tahir Amin and Priti Krishtel, headquartered in Lewes, Delaware. The organization works on drug patent reform and access to medicines, producing policy research and litigation support aimed at reducing what it characterizes as anticompetitive pharmaceutical patent practices. Its work spans 49 countries and explicitly excludes pharmaceutical industry funding to preserve independence.

I-MAK's core analytical product is the Drug Patent Book, a curated patent database that underpins its published research outputs. These reports include "Overpatented, Overpriced" (with a 2025 edition focused on Medicare-negotiated drugs), "The Burden of Patent Thickets" (estimating ~$158 billion in cost burden), "The Costs of Pharma Cheating" (produced with the American Economic Liberties Project, estimating ~$40 billion annually), and "The Monopoly Extension Menu" on patent term extension strategies. The organization operates with a small team of 1-10 employees and is funded by a diversified base of major philanthropic foundations including the Ford Foundation, Open Society Foundations, Rockefeller Brothers Fund, Kaiser Permanente, and Arnold Ventures.

The business model is donation- and grant-based rather than commercial. I-MAK does not sell its reports or database access as revenue products; rather, it distributes research to influence regulators (notably the FTC and the Centers for Medicare & Medicaid Services), inform litigation, and shape media and policy discourse on drug pricing. Strategic significance derives from its role as a credible, independent counterweight to pharmaceutical industry patent strategy, with measurable downstream influence on U.S. drug-price negotiation policy.

I-Mak firmographics

Firmographics
Name
I-Mak
Legal name
Initiative for Medicines, Access, and Knowledge
Website
https://i-mak.org
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
I-MAK is a 501(c)(3) nonprofit advocacy organization that conducts drug patent research and policy work to challenge anticompetitive pharmaceutical patenting, serving regulators, policymakers, litigators, journalists, and patient advocates across 49 countries.
Ownership category
akta.pro rank

I-Mak industry classification

Industry
Product category
Pharmaceutical Patent Research and Advocacy
NAICS
Scientific Research and Development Services (5417), Book Publishers (51313)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPAHAMAI
IP Search, Watch & Competitive Intelligence
SECONDARYMPAJACAK
IP & Patent Information Publishing (Patent/Litigation Analytics, Prior Art)
Media, Entertainment & Sports/Publishing (Books, News, Magazines)/Professional & Legal Publishing (Standards, Compliance, Reference)

Keywords

  • Drug patent research
  • Pharmaceutical patent analytics
  • Patent reform advocacy
  • Drug pricing transparency
  • Medicines access policy

Where I-Mak is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

I-Mak business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Charitable Contributions and Grants: I-MAK is a 501(c)(3) nonprofit organization that relies on charitable contributions from foundations and individuals. The organization explicitly states they do not accept funding from branded or generic pharmaceutical companies to maintain independence and exclusively represent the interests of patients and consumers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

I-Mak product offering

Product offering

Core offering

I-MAK conducts rigorous research on pharmaceutical patenting practices and operates the Drug Patent Book, a publicly accessible database tracking patent applications, granted patents, pricing, and spending data on top-selling prescription drugs in the U.S. The organization publishes annual research reports (Overpatented, Overpriced series), policy blueprints, and educational resources, and engages in advocacy and Congressional testimony to drive patent system reform aimed at lowering drug prices and expanding access to affordable medicines.

Product overview

I-MAK (Initiative for Medicines, Access, and Knowledge) is a nonprofit research and advocacy organization focused on patent reform and drug pricing transparency. The organization operates primarily through research and data products rather than a unified software platform. Its core offerings include The Drug Patent Book, a comprehensive publicly accessible database of drug patent information; annual Overpatented, Overpriced reports analyzing pharmaceutical patent abuse; The Burden of Patent Thickets study quantifying the $158 billion cost of extended patent protection; and the Addressing Patent Thickets Blueprint presenting policy solutions. These products work together to provide transparency on pharmaceutical patenting practices, educate stakeholders, and inform policy reform efforts aimed at lowering drug prices through patent system improvements.

Differentiator

Problem solved

Functional benefit

Brands

  • Drug Patent Book: A publicly accessible, user-friendly database providing comprehensive patent data on top-selling prescription drugs in the U.S.
  • Overpatented, Overpriced

Products and services

  • The Drug Patent Book A publicly accessible, user-friendly database providing comprehensive patent data on top-selling prescription drugs in the U.S., including patent applications, granted patents, filing dates, expiration dates, pricing, and spending information. Used by researchers, policymakers, journalists, and patient advocates.
  • Overpatented, Overpriced Reports Annual analyses documenting how pharmaceutical manufacturers use patent strategies to extend monopoly pricing on drugs beyond original patent terms, with case studies on specific medications.
  • The Burden of Patent Thickets Study A study exposing the $158 billion in revenue extracted by drugmakers on four biologic drugs (Humira, Avastin, Rituxan, and Lantus) through extended patent protection limiting biosimilar competition.
  • Addressing Patent Thickets Blueprint A policy document presenting policymakers with approaches to address patent thickets, improve competition, and lower prescription drug prices through patent system reforms.
  • Overpatented 2025: Eliquis and Semaglutide Analysis A 2025 data brief analyzing patenting and pricing practices for Medicare-negotiated drugs Eliquis, Ozempic, Rybelsus, and Wegovy, examining patent term extensions and follow-on patenting strategies.
  • The Costs of Pharma Cheating Report A co-authored report with American Economic Liberties Project exposing how pharmaceutical companies combine abusive patenting strategies with anti-competitive tactics, estimating $40 billion annual cost to the American public.
  • Biologics, Biosimilars and Patents: A Beginner's Guide A beginner's guide explaining how biologics and biosimilars work and their relationship to the patent system.
  • America's Top Selling Drugs Data Resource A collection of statistics including market dynamics, pricing, spending data, and patent information for the top 10 best-selling drugs in America.
  • Drug Pricing Survey Data Survey data on drug pricing concerns, providing public insights into pharmaceutical pricing issues.

Quantifiable outcome

  • Research cited in major media including NYT, TIME, Reuters, NBC, and featured in Congressional hearings
  • +3 more outcomes

Companies that use I-Mak

Customer profile

Segments4 records

Ideal customer profiles4 records

I-Mak technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

I-Mak partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered supporting and core.

  • Medecins Sans Frontiere (MSF)supportingStrategic or Co-development PartnerMSF (Doctors Without Borders) is listed as an I-MAK supporter, aligning on access to medicines issues globally.
  • American Economic Liberties ProjectcoreStrategic or Co-development PartnerI-MAK partnered with the American Economic Liberties Project on 'The Costs of Pharma Cheating' report, exposing how pharmaceutical industry abusive patenting tactics violate antitrust laws and cost Americans $40 billion annually.
  • Protect Our CaresupportingStrategic or Co-development PartnerI-MAK provided data and analysis for Protect Our Care's report highlighting the impact Medicare negotiations will have on lowering drug prices and curbing patent abuse.
  • Public CitizensupportingStrategic or Co-development PartnerI-MAK partnered with Public Citizen on advocacy letters to Senator Schumer calling for insulin reforms and drug pricing legislation.
  • AARP and Patients for Affordable Drugs NowsupportingStrategic or Co-development PartnerI-MAK joined with AARP and Patients for Affordable Drugs Now in joint letters urging Senate action to lower drug prices.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

I-Mak competitors and assessment

Company assessment

Direct peers

  • Public Citizen: U.S. consumer advocacy nonprofit running a long-running access-to-medicines program that campaigns on drug pricing, opposes pharma patent abuse, and has partnered with I-MAK on Congressional advocacy. Direct peer in mission and tactics.
  • Knowledge Ecology International (KEI): Nonprofit focused on IP policy and access-to-medicines issues, conducts original research on drug patenting and participates in WIPO/WTO deliberations. Directly comparable to I-MAK in patent-research and policy-advocacy niche.
  • MSF Access Campaign: The access-to-medicines arm of Doctors Without Borders; campaigns against pharma patent abuse, supports pool patents, and is listed as a mutual supporter of I-MAK. Operates in the same advocacy space with similar quantitative-impact framing.
  • Patients For Affordable Drugs Now: U.S. patient-led advocacy organization pushing for drug-price reform and patent transparency; has co-signed advocacy letters with I-MAK. Directly comparable mission and Congressional-engagement model.
  • American Economic Liberties Project: Anti-monopoly advocacy organization that co-authored 'The Costs of Pharma Cheating' with I-MAK. Operates in adjacent antitrust/competition space but with direct collaboration on I-MAK's patent-reform reports.

Emerging players

  • Drug Pricing Lab at Memorial Sloan Kettering: Peter Bach's drug-pricing research initiative producing data-driven analyses on U.S. drug costs and policy. Comparable in producing evidence-based research on drug-pricing economics, though not patent-system-focused.
  • Third World Network: International policy NGO focused on development issues including access-to-medicines and IP reform. Comparable in publishing analyses on drug patenting for global policy audiences, primarily outside the U.S.
  • Health GAP (Global Access Project): U.S.-based AIDS access advocacy organization with similar mission around pharmaceutical pricing transparency, particularly in HIV. Comparable in advocacy tactics though narrower therapeutic focus.
  • CIVIC (Center for Information and Innovation on the Pharmaceutical Industry) at USC Schaeffer: Academic research center producing independent analysis of pharmaceutical industry economics and policy. Comparable in producing evidence on drug pricing and IP issues though academic rather than advocacy orientation.

Broad incumbents

  • DrugPatentWatch: Commercial patent-analytics subscription service providing patent and exclusivity data on pharmaceuticals. Overlaps with I-MAK's Drug Patent Book but operates commercially with broader drug coverage; comparable product category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

I-Mak social profiles

Digital presence

I-Mak financial estimates

Financial estimate

Revenue estimate

Valuation estimate

I-Mak leadership team

Management profile

Number of profiles

Profiles3 records

I-Mak funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

I-Mak M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about I-Mak

What does I-Mak do?

I-MAK conducts rigorous research on pharmaceutical patenting practices and operates the Drug Patent Book, a publicly accessible database tracking patent applications, granted patents, pricing, and spending data on top-selling prescription drugs in the U.S. The organization publishes annual research reports (Overpatented, Overpriced series), policy blueprints, and educational resources, and engages in advocacy and Congressional testimony to drive patent system reform aimed at lowering drug prices and expanding access to affordable medicines.

Is I-Mak a public or private company?

I-Mak is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was I-Mak founded?

I-Mak was founded in 2004. It employs 1 to 10 people.

Where is I-Mak based?

I-Mak is headquartered in New York, United States, in the North America region.

How does I-Mak make money?

One revenue line is on record: charitable Contributions and Grants.

Who are I-Mak's main competitors?

Direct peers on record are Public Citizen, Knowledge Ecology International (KEI), MSF Access Campaign, Patients For Affordable Drugs Now and American Economic Liberties Project. Emerging players are Drug Pricing Lab at Memorial Sloan Kettering, Third World Network, Health GAP (Global Access Project) and CIVIC (Center for Information and Innovation on the Pharmaceutical Industry) at USC Schaeffer. DrugPatentWatch is listed as a broad incumbent.

Does I-Mak have an API?

No public API is recorded for I-Mak.

What industry is I-Mak in?

I-Mak's product category is Pharmaceutical Patent Research and Advocacy. Its primary akta.pro industry code is BPAHAMAI, IP Search, Watch & Competitive Intelligence, with a secondary code of MPAJACAK, IP & Patent Information Publishing (Patent/Litigation Analytics, Prior Art). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals